Clinical Status and Optimal Use of Rituximab for B-Cell Lymphomas

ONCOLOGY

Volumn 12, Issue 12, 1998, Pages 1763-1769

  McLaughlin, Peter ^a   White, Christine A ^a   Grillo López, Antonio J ^a   Maloney, David G ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG INDUCED DISEASE; FOOD AND DRUG ADMINISTRATION; HUMAN; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, B-CELL;

EID: 0032447240     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Dillman RO: Antibodies as cytotoxic therapy. J Clin Oncol 12:1497-1515, 1994.
2. Anderson K, Bates M, Slaughenhoup B, et al: Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 63:1424-1433, 1984.
3. Grossbard M, Press O, Appelbaum F, et al: Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863-878, 1992.
4. Press O, Appelbaum F, Ledbetter J, et al: Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas. Blood 69:584-591, 1987.
5. Reff ME, Carner K, Chambers KS, et al: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435-445, 1994.
6. Stashenko P, Nadler LM, Hardy R, et al: Characterization of a human B- lymphocyte-specific antigen. J Immunol 125:1678-1685, 1980.
7. Einfeld D, Brown J, Valentine M, et al: Molecular cloning of the human B-cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7:711-717, 1988.
8. Zhou L-J, Tedder TF: CD20 workshop panel report, in Schlossman SF, Boumsell L, Gilks W, et al (eds): Leucocyte Typing V, White Cell Differentiation Antigens, pp 511-514. Oxford. Oxford University Press, 1995.
9. Tedder T, Boyd A, Freedman A, et al: The B-cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 135:973-979, 1985.
10. Golay JT, Clark EA, Beverley PC: The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol 135: 3795-3801, 1985.
11. Maloney DG, Smith B, Appelbaum FR: The anti-tumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines (abstract). Blood 88(suppl 1):637a, 1996.
12. Demidem A, Lam T, Alas S, et al: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12:177-186, 1997.
13. Maloney DG, Liles TM, Czerwinski DK, et al: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84: 2457-2466, 1994.
14. Maloney DG, Grillo-López AJ, Bodkin DJ, et al: IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15: 3266-3274, 1997.
15. Maloney DG, Grillo-López AJ, White CA, et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997.
16. McLaughlin P, Cabanillas F, Grillo-López AJ et al: Pharmacokinetics and pharmacodynamics of the anti-CD20 antibody IDEC-C2B8 in patients with relapsed low-grade or follicular lymphoma (abstract). Blood 88(suppl 1):90a, 1996.
17. McLaughlin P, Cabanillas F, Grillo-López, AJ, et al: IDEC-C2B8 anti-CD20 antibody: Final report on a phase III pivotal trial in patients with relapsed low-grade or follicular lymphoma (abstract). Blood 88(suppl 1):90a, 1996.
18. Almasri NM, Duque RE, Iturraspe J, et al: Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 40:259-63, 1992.
19. Piro L, White CA, Grillo-López AJ, et al: Rituxan (rituximab, IDEC-C2B8): Interim analysis of a phase II study of once weekly times eight dosing in patients with relapsed low-grade or follicular non-Hodgkin's lymphoma (abstract). Blood 90 (suppl 1):510a, 1997.
20. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998.
21. Czuczman MS, Grillo-López AJ, Saleh M, et al: IDEC-C2B8/CHOP chemoimmunotherapy in patients with low-grade lymphoma: Interim clinical and bcl-2 (PCR) results (abstract). Ann Oncol 7(suppl 1):56, 1996.
22. McLaughlin P, Grillo-López, AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a 4-dose treatment program. J Clin Oncol 16:2825-2833, 1998.
23. Horning S, Cheson B, Peterson B, et al: Response criteria and quality assurance of responses in the evaluation of new therapies for patients with low-grade lymphoma (abstract). Proc Am Soc Clin Oncol 16:18a, 1997.
24. Dillman RO: The human antimouse response. Antibody Immunocon Radiopharm 3:1-15, 1990.
25. Ezdinli EZ, Anderson JR, Melvin F, et al: Moderate vs aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol 3: 769-775, 1985.
26. Portlock CS, Fischer DS, Cadman E, et al: High-dose pulse chlorambucil in advanced, low-grade non-Hodgkin's lymphoma. Cancer Treat Rep 71: 1029-1031, 1987.
27. McLaughlin P, Robertson LE, Keating JM: Fludarabine phosphate in lymphoma: An important new therapeutic agent, in Cabanillas F, Rodriguez MA (eds): Advances in Lymphoma Research, pp 3-14. Boston, Kluwer Academic Publishers, 1996.
28. Pott-Hoeck C, Hiddemann W: Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. Ann Oncol 6:421-433, 1995.
29. Piro LD: Cladribine in the treatment of low-grade non-Hodgkin's lymphoma. Semin Hematol 33(suppl 1):34-39, 1996.
30. Kalter S, Holmes L, Cabanillas F: Long-term results of treatment of patients with follicular lymphomas. Hematol Oncol 5:127-138, 1987.
31. Anderson KC, Skarin AT, Rosenthal DS, et al: Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies. Cancer Treat Rep 68: 1343-150, 1984.
32. McLaughlin P, Hagemeister FB, Romaguera JE, et al: Fludarabine, mitoxantrone. and dexa-methasone: An effective new regimen for indolent lymphoma. J Clin Oncol 14:1262-1268, 1996.
33. McLaughlin P, Hagemeister FB, Swan F, et al: Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: High remission rates and reversion to negative of peripheral blood bcl-2 rearrangement. Ann Oncol 5(suppl 2): S73-S77, 1994.
34. Horning SJ: High-dose therapy and transplantation for low-grade lymphoma. Hematol Oncol Clin N Am 11:919-935, 1997.
35. Davis T, Levy R, White CA, et al: Retreatments with Rituxan (rituximab. IDEC-C2B8) have significant efficacy, do not cause HAMA, and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma (abstract). Blood 90(suppl 1):509a, 1997.
36. Davis T, Maloney D, White CA, et al: Combination immunotherapy of low grade or follicular non-Hodgkin's lymphoma with rituximab and alpha-interferon: Interim analysis (abstract). Proc Am Soc Clin Oncol 17:11a, 1998.
37. Link BK, Grossbard ML, Fisher RI, et: Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate- or high-grade NHL. Proc Am Soc Clin Oncol 17:3a, 1998.